HDAC overexpression has been detected in a broad range of cancers and is often associated with poor outcomes and shorter survival, including gastric cancer, ovarian cancer, prostate cancer, and multiple myeloma, etc.19–21,40. This evidence concerns the gene HDAC9 and prostate cancer.